Lactobacillus acidophilus CHO-220 and inulin reduced plasma total cholesterol and low-density lipoprotein cholesterol via alteration of lipid transporters
Lactobacillus acidophilus CHO-220 and inulin reduced plasma total cholesterol and low-density lipoprotein cholesterol via alteration of lipid transporters
复制标题
DOI：
10.3168/jds.2010-3311
复制
发表时间：
2010-11-01
影响因子：
3.5
通讯作者：
Liong, M. -T.
中科院分区：
文献类型：
--
作者：
Ooi, L. -G.;Ahmad, R.;Liong, M. -T.
这项随机、双盲、安慰剂对照、平行设计的研究旨在研究含有嗜酸乳杆菌CHO-220和菊粉的合成产品对高胆固醇血症男性和女性的脂质谱的影响。32名初始平均血浆胆固醇水平为5.7 +/- 0.32 mmol/L的高胆固醇血症男性和女性被招募参加为期12周的研究。受试者随机分为2组；即治疗组（合成制剂）和对照组（安慰剂），每天各服用4粒合成制剂或安慰剂。我们的研究结果显示，在研究期间，两组受试者的平均体重、能量和营养摄入量没有差异。在12周内，与对照组相比，添加合成菌可使血浆总胆固醇和低密度脂蛋白(LDL)-胆固醇分别降低7.84%和9.27%。脂蛋白随后被分离并表征。合成菌的补充导致甘油三酯浓度在极低，中等，低；并且高密度脂蛋白颗粒在12周内与对照组比较。脂蛋白中甘油三酯的浓度与动脉粥样硬化风险增加呈正相关。我们的研究结果表明，这种合成物可能具有预防动脉粥样硬化的特性。与对照组相比，合成组高密度脂蛋白颗粒中的胆固醇酯（CE）也更高，表明胆固醇以CE的形式更多地转运到肝脏进行水解。这可能导致合成组血浆总胆固醇水平降低。与对照组相比，合成菌的补充也降低了LDL颗粒中CE的浓度，导致形成更小、更密集的颗粒，更容易从血液中去除。这支持了与对照组相比，合成组降低了ldl -胆固醇水平。我们目前的研究表明，合成产物通过改变脂质转运体的相互联系途径来改善血浆总胆固醇和低密度脂蛋白胆固醇水平。此外，虽然嗜酸乳杆菌CHO-220可以解结胆汁，但我们的研究结果显示，在12周内，合成组和对照组之间共轭胆汁酸、解结胆汁酸、初级胆汁酸和次级胆汁酸的水平差异在统计学上不显著，表明胆相关毒性是安全的。
This randomized, double-blind, placebo-controlled, and parallel-designed study was conducted to investigate the effect of a synbiotic product containing Lactobacillus acidophilus CHO-220 and inulin on lipid profiles of hypercholesterolemic men and women. Thirty-two hypercholesterolemic men and women with initial mean plasma cholesterol levels of 5.7 +/- 0.32 mmol/L were recruited for the 12-wk study. The subjects were randomly allocated to 2 groups; namely the treatment group (synbiotic product) and the control group (placebo), and each received 4 capsules of synbiotic or placebo daily. Our results showed that the mean body weight, energy, and nutrient intake of the subjects did not differ between the 2 groups over the study period. The supplementation of synbiotic reduced plasma total cholesterol and low-density lipoprotein (LDL)-cholesterol by 7.84 and 9.27%, respectively, compared with the control over 12 wk. Lipoproteins were subsequently subfractionated and characterized. The synbiotic supplementation resulted in a lower concentration of triglycerides in the very low, intermediate, low; and high-density lipoprotein particles compared with the control over 12 wk. The concentration of triglycerides in lipoproteins is positively correlated with an increased risk of atherosclerosis. Our results showed that the synbiotic might exhibit an atheropreventive characteristic. Cholesteryl ester (CE) in the high-density lipoprotein particles of the synbiotic group was also higher compared with the control, indicating greater transport of cholesterol in the form of CE to the liver for hydrolysis. This may have led to the reduced plasma total cholesterol level of the synbiotic group. The supplementation of synbiotic also reduced the concentration of CE in the LDL particles compared with the control, leading to the formation of smaller and denser particles that are more easily removed from blood. This supported the reduced LDL-cholesterol level of the synbiotic group compared with the control. Our present study showed that the synbiotic product improved plasma total- and LDL-cholesterol levels by modifying the interconnected pathways of lipid transporters. In addition, although Lactobacillus acidophilus CHO-220 could deconjugate bile, our results showed a statistically insignificant difference in the levels of conjugated, deconjugated, primary, and secondary bile acids between the synbiotic and control groups over 12 wk, indicating safety from bile-related toxicity.